TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of TRACON Pharmaceuticals stock opened at $0.03 on Thursday. TRACON Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $14.75. The company has a market cap of $100,536.00, a P/E ratio of 0.01 and a beta of 1.43. The company’s fifty day simple moving average is $0.08 and its two-hundred day simple moving average is $0.56.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.